WASHINGTON, D.C. — The U.S. Department of Commerce has added BGI Group Co., a Chinese genomics leader, to its Entity List, prohibiting American companies from providing technology or components without a license. The move follows accusations that BGI uses forced labor from Uighur minorities.

BGI, which operates 12 sequencing labs worldwide and reported 2022 revenue of $2.5 billion, has long supplied genetic testing kits to U.S. hospitals. The new restriction blocks the export of next‑generation sequencers and associated reagents, effectively halting all shipments destined for the United States.

KEY POINTBGI, which operates 12 sequencing labs worldwide and reported 2022 revenue of $2.

In a statement, Commerce Secretary Gina Haspel said the decision is “rooted in the protection of human rights and the integrity of our supply chain.” She cited a report from the U.S. Senate that identified BGI’s facilities in Xinjiang as sites where “involuntary labor” was documented.

Analysts warn that the ban could ripple through the biotech sector. Venture‑capital firms that have invested in BGI’s American subsidiaries face a sudden loss of access to a major customer base, while U.S. researchers may lose a key supplier for high‑throughput sequencing services.

BGI’s spokesperson, Li Wei, dismissed the allegations as “politically motivated attacks” and pledged “to cooperate fully with international human‑rights investigations.” The company has announced plans to establish a new research hub in Singapore to mitigate the impact of the sanctions.

Key Takeaways

• BGI added to U.S. Entity List; all exports to the U.S. now prohibited without license.
• Allegations of forced labor in Xinjiang underpin the decision.
• U.S. biotech firms and investors may face supply‑chain disruptions and financial losses.

The restriction underscores a growing trend of technology‑trade limits aimed at curbing firms linked to human‑rights abuses. Market watchers expect further scrutiny of Chinese companies in the genomics space, potentially reshaping global collaboration in genetic research.